Adagio Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 11, 2024, reports material executive leadership changes at Adagio Medical Holdings, Inc. (ADGM). The filing details the resignation of the Chief Executive Officer (CEO) and Chairman of the Board, and the subsequent appointment of a new CEO and Director, effective December 13, 2024.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and corporate governance changes.
Material Changes
- Departure of CEO and Chairman: Olav Bergheim resigned as CEO and Chairman effective December 13, 2024. The resignation was not due to any disagreement regarding financial reporting or operations.
- Appointment of New CEO: Todd Usen was appointed CEO and Class I Director effective December 13, 2024.
- Board Leadership Change: Orly Mishan, a current director, was appointed Chairperson of the Board effective December 13, 2024.
Compensation, Outlook, and Risks
Outgoing CEO Compensation (Olav Bergheim):
- Base cash severance: $1,200,000.
- Conditional cash severance: $300,000, payable upon a Change in Control, equity financing, or qualifying licensing transaction.
- Advisory Role: 12-month term as an independent contractor.
- Equity: Option to purchase 338,398 shares of common stock as sole compensation for advisory services.
- Benefits: Health insurance through the end of the month of separation and COBRA premium reimbursement.
Incoming CEO Compensation (Todd Usen):
- Base Salary: $500,000 per year.
- Performance Bonus: Up to 50% of base salary (discretionary).
- Financing Bonus: 16% of base salary, conditioned on successful equity financing or approved business development transactions.
- Relocation: Up to $100,000.
- Equity: Option to purchase shares representing approximately 5% of fully diluted shares outstanding.
Management Commentary: The Board highlighted Mr. Usen's extensive experience in medical device companies, including restructuring Minerva Surgical and leading fundraising efforts at Activ Surgical and Olympus Corporation. The filing states the selection was not pursuant to any arrangement with other persons.
Investor Verification Checklist
- Verify the exact terms of the "Change in Control" and "equity financing" conditions triggering the $300,000 severance for Mr. Bergheim.
- Confirm the specific gross proceeds threshold required for Mr. Usen's 16% financing bonus.
- Review the full text of the Separation Agreement (Exhibit 10.1) and Offer Letter (Exhibit 10.2) for restrictive covenants and non-compete clauses.
- Monitor upcoming filings for the Company's capital position, as the new CEO's compensation is heavily tied to future financing events.